Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa

dc.contributor.authorNjuguna, Christine
dc.contributor.authorSwart, Annoesjka
dc.contributor.authorBlockman, Marc
dc.contributor.authorMaartens, Gary
dc.contributor.authorChisholm, Briony
dc.contributor.authorStewart, Annemie
dc.contributor.authorUys, Anri
dc.contributor.authorCohen, Karen
dc.date.accessioned2017-03-16T12:12:24Z
dc.date.available2017-03-16T12:12:24Z
dc.date.issued2016-11-16
dc.date.updated2016-11-16T19:02:13Z
dc.description.abstractBackground: Gynaecomastia is associated with exposure to antiretroviral therapy (ART), in particular efavirenz. There is limited data on clinical characteristics of patients with ART-associated gynaecomastia in resource-limited settings and little guidance on the optimal management of this adverse drug reaction (ADR). We describe the clinical characteristics, management and outcomes of gynaecomastia cases reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa. Methods: We identified all gynaecomastia cases in adolescent boys and men on ART reported to the hotline between June 2013 and July 2014. We collected follow up data telephonically at monthly intervals to document clinical management and outcomes. Results: We received 51 reports of gynaecomastia between June 2013 and July 2014; 11% of the 475 patient-specific ADR queries to the hotline. All patients were on efavirenz-based ART. Mean age was 34 years (standard deviation 12) and seven were adolescents. The median onset of gynaecomastia was 15 months after efavirenz initiation (interquartile range 6–42). Gynaecomastia was bilateral in 29 patients (57%) and unilateral in 16 (31%). Serum testosterone was quantified in 25 of 35 patients with follow up data, and was low in 2 (8%). Efavirenz was replaced with an alternative antiretroviral in 29/35 patients (83%) and gynaecomastia improved in 20/29 (69%). Conclusions: Gynaecomastia was a frequently reported ADR in our setting, occurring with prolonged efavirenz exposure. Testosterone was low in the minority of tested cases. Most clinicians elected to switch patients off efavirenz, and gynaecomastia improved in the majority.
dc.identifier.apacitationNjuguna, C., Swart, A., Blockman, M., Maartens, G., Chisholm, B., Stewart, A., ... Cohen, K. (2016). Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa. <i>AIDS Research and Therapy</i>, http://hdl.handle.net/11427/24048en_ZA
dc.identifier.chicagocitationNjuguna, Christine, Annoesjka Swart, Marc Blockman, Gary Maartens, Briony Chisholm, Annemie Stewart, Anri Uys, and Karen Cohen "Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa." <i>AIDS Research and Therapy</i> (2016) http://hdl.handle.net/11427/24048en_ZA
dc.identifier.citationNjuguna, C., Swart, A., Blockman, M., Maartens, G., Chisholm, B., Stewart, A., ... & Cohen, K. (2016). Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa. AIDS research and therapy, 13(1), 40.
dc.identifier.ris TY - Journal Article AU - Njuguna, Christine AU - Swart, Annoesjka AU - Blockman, Marc AU - Maartens, Gary AU - Chisholm, Briony AU - Stewart, Annemie AU - Uys, Anri AU - Cohen, Karen AB - Background: Gynaecomastia is associated with exposure to antiretroviral therapy (ART), in particular efavirenz. There is limited data on clinical characteristics of patients with ART-associated gynaecomastia in resource-limited settings and little guidance on the optimal management of this adverse drug reaction (ADR). We describe the clinical characteristics, management and outcomes of gynaecomastia cases reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa. Methods: We identified all gynaecomastia cases in adolescent boys and men on ART reported to the hotline between June 2013 and July 2014. We collected follow up data telephonically at monthly intervals to document clinical management and outcomes. Results: We received 51 reports of gynaecomastia between June 2013 and July 2014; 11% of the 475 patient-specific ADR queries to the hotline. All patients were on efavirenz-based ART. Mean age was 34 years (standard deviation 12) and seven were adolescents. The median onset of gynaecomastia was 15 months after efavirenz initiation (interquartile range 6–42). Gynaecomastia was bilateral in 29 patients (57%) and unilateral in 16 (31%). Serum testosterone was quantified in 25 of 35 patients with follow up data, and was low in 2 (8%). Efavirenz was replaced with an alternative antiretroviral in 29/35 patients (83%) and gynaecomastia improved in 20/29 (69%). Conclusions: Gynaecomastia was a frequently reported ADR in our setting, occurring with prolonged efavirenz exposure. Testosterone was low in the minority of tested cases. Most clinicians elected to switch patients off efavirenz, and gynaecomastia improved in the majority. DA - 2016-11-16 DB - OpenUCT DO - 10.1186/s12981-016-0121-z DP - University of Cape Town J1 - AIDS Research and Therapy LK - https://open.uct.ac.za PB - University of Cape Town PY - 2016 T1 - Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa TI - Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa UR - http://hdl.handle.net/11427/24048 ER - en_ZA
dc.identifier.urihttp://dx.doi.org/10.1186/s12981-016-0121-z
dc.identifier.urihttp://hdl.handle.net/11427/24048
dc.identifier.vancouvercitationNjuguna C, Swart A, Blockman M, Maartens G, Chisholm B, Stewart A, et al. Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa. AIDS Research and Therapy. 2016; http://hdl.handle.net/11427/24048.en_ZA
dc.language.rfc3066en
dc.publisherBioMed Central
dc.publisher.departmentDepartment of Medicineen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.rights.holderThe Author(s)
dc.sourceAIDS Research and Therapy
dc.source.urihttps://aidsrestherapy.biomedcentral.com/
dc.subject.otherGynaecomastia
dc.subject.otherAntiretroviral therapy
dc.subject.otherEfavirenz
dc.subject.otherSouth Africa
dc.titleCases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa
dc.typeJournal Article
uct.type.filetype
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Njuguna_2016_Article.pdf
Size:
798.19 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.72 KB
Format:
Item-specific license agreed upon to submission
Description:
Collections